Amyloid-related imaging abnormalities in the era of anti-amyloid beta monoclonal antibodies for Alzheimer's disease: recent updates on clinical and imaging features …
Recent advancements in Alzheimer's disease treatment have focused on the elimination of
amyloid-beta (Aβ) plaque, a hallmark of the disease. Monoclonal antibodies such as …
amyloid-beta (Aβ) plaque, a hallmark of the disease. Monoclonal antibodies such as …
Risk factors in develo** amyloid related imaging abnormalities (ARIA) and clinical implications
SJ Doran, RP Sawyer - Frontiers in Neuroscience, 2024 - frontiersin.org
Alzheimer's disease (AD) affects over 6 million people over the age of 65. The advent of new
anti-amyloid monoclonal antibodies as treatment for early Alzheimer's disease these …
anti-amyloid monoclonal antibodies as treatment for early Alzheimer's disease these …
[HTML][HTML] Intrathecal Immunoselective Nanopheresis for Alzheimer's Disease: What and How? Why and When?
M Menendez-Gonzalez - International Journal of Molecular Sciences, 2024 - mdpi.com
Nanotechnology is transforming therapeutics for brain disorders, especially in develo**
drug delivery systems. Intrathecal immunoselective nanopheresis with soluble monoclonal …
drug delivery systems. Intrathecal immunoselective nanopheresis with soluble monoclonal …
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
A Wicker, J Shriram, B Decourt, MN Sabbagh - Neurology and Therapy, 2024 - Springer
Alzheimer's disease (AD) is a neurodegenerative disorder that significantly impairs cognitive
and functional abilities, placing a substantial burden on both patients and caregivers …
and functional abilities, placing a substantial burden on both patients and caregivers …
Updated imaging markers in cerebral amyloid angiopathy: What radiologists need to know
F Tanaka, M Maeda, S Kishi, R Kogue, M Umino… - Japanese Journal of …, 2024 - Springer
Cerebral amyloid angiopathy (CAA) is an age-related small vessel disease pathologically
characterized by the progressive accumulation of amyloid-beta (Aβ) peptide in …
characterized by the progressive accumulation of amyloid-beta (Aβ) peptide in …
Immunotherapy: An emerging treatment option for neurodegenerative diseases
A Mukherjee, S Biswas, I Roy - Drug Discovery Today, 2024 - Elsevier
Highlights•Levels of protein aggregates in neurodegenerative diseases can be lowered with
antibodies.•Bioavailability, rather than efficacy, is the major area of concern.•Transferrin …
antibodies.•Bioavailability, rather than efficacy, is the major area of concern.•Transferrin …
[HTML][HTML] Lecanemab: appropriate use recommendations by Korean Dementia Association
Lecanemab (product name Leqembi®) is an anti-amyloid monoclonal antibody treatment
approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia …
approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia …
[HTML][HTML] Initial experience with lecanemab and lessons learned in 71 patients in a regional medical center
LBE Shields, H Hust, SD Cooley, GE Cooper… - The journal of …, 2024 - Elsevier
Abstract Background and Objectives On July 6, 2023 the US Food and Drug Administration
approved the anti-amyloid monoclonal antibody lecanemab (Leqembi®) for treatment of …
approved the anti-amyloid monoclonal antibody lecanemab (Leqembi®) for treatment of …
Current insights into apolipoprotein E and the immune response in Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurological disorder and the most common
cause of dementia. Genetic analyses identified apolipoprotein E (APOE) as the strongest …
cause of dementia. Genetic analyses identified apolipoprotein E (APOE) as the strongest …
Development, physico-chemical characterization, and in vivo stability of a novel aglycosylated monoclonal antibody targeting FAM19A5
WK Kim, JY Seong, GM Lee - Biotechnology and Bioprocess Engineering, 2024 - Springer
Introducing aglycosylation into therapeutic monoclonal antibodies (mAbs) can prevent side
effects associated with fragment crystallizable (Fc)-mediated effector functions. This …
effects associated with fragment crystallizable (Fc)-mediated effector functions. This …